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We conducted a nested case-control study within two prospective cohorts, the New York University Women’s Health Study and
the Northern Sweden Health and Disease Study, to examine the association between prediagnostic circulating levels of 25-hydroxy
vitamin D (25(OH)D) and the risk of subsequent invasive epithelial ovarian cancer (EOC). The 25(OH)D levels were measured
in serum or plasma from 170 incident cases of EOC and 373 matched controls. Overall, circulating 25(OH)D levels were not
associated with the risk of EOC in combined cohort analysis: adjusted OR for the top tertile versus the reference tertile, 1.09 (95%
CI,0.59–2.01).Inaddition,therewasnoevidenceofaninteractioneﬀectbetweenVDRSNPgenotypeorhaplotypeandcirculating
25(OH)D levels in relation to ovarian cancer risk, although more complex gene-environment interactions may exist.
Copyright © 2009 Alan A. Arslan et al. This is an open access article distributed under the Creative Commons AttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
There is considerable interest in understanding the role of
vitamin D in cancer in general and in ovarian cancer in
particular. Experimental studies have shown that vitamin D
administrationreducesproliferationandpromotesapoptosis
inovariancancercelllinesandanimalmodels[1–6].Ovarian
cancer incidence and mortality rates are higher in northern
latitudes, where sun exposure, which is required for the
initiation of vitamin D synthesis in the skin, is lower
[7–10]. An inverse association between dietary vitamin D
intake and risk of ovarian cancer has been reported in
one epidemiologic study [11], although others have not
supported this ﬁnding [12–16]. Studies of the eﬀect of
dietary vitamin D intake are limited because estimation
of dietary vitamin D intake does not capture cutaneous
production of vitamin D. Thus, circulating vitamin D, which
reﬂects both cutaneous production and dietary/supplement
intake [17–20], is considered the best indicator of overall
vitamin D status.
1,25(OH)2D is the biologically active vitamin D metabo-
lite. However, its concentration is about 1000 times lower
than that of 25(OH)D in circulation, due to its shorter half-
life and local production in target tissues, such as the ovaries
[21, 22]. Thus, 25(OH)D is thought to better reﬂect overall
vitamin D status than 1,25(OH)2 D[ 23, 24].
To date, only one epidemiologic study has examined
the relationship between prediagnostic levels of vitamin D
and risk of ovarian cancer. Tworoger et al. did not ﬁnd an
association of ovarian cancer risk with the 25(OH)D or 1,25-
dihydroxyvitamin D (1,25(OH)2D) plasma levels [25].
Polymorphisms in the VDR gene may inﬂuence the
ability of 1,25(OH)2D to activate vitamin D target genes,
including those involved in growth regulation and apoptosis.
In a previous manuscript, we reported an overall null
association between four common polymorphisms in the2 Journal of Oncology
VDR gene (Bsm1, Apa1, Taq1,a n dFok1) and risk of ovarian
cancer [26], although a retrospective multiethnic study
of 313 cases and 574 controls [27]a n dal a r g ep o o l e d
analysis including 1473 cases and 2006 controls from four
studies (one retrospective case-control study and three case-
control studies nested in prospective cohorts) [28]f o u n da n
association with the Fok1 SNP among Caucasian women.
Mixed results for this and other VDR SNPs may be due
to chance ﬁndings or limited power to detect associations
[27]. It is also possible that genetic variants inﬂuence ovarian
cancer risk diﬀerently, depending on an individual’s vitamin
D status.
The objective of the present study was to examine the
relationship between circulating levels of 25(OH)D and
risk of invasive epithelial ovarian cancer and to assess
the combined eﬀect of circulating 25(OH)D and VDR
polymorphisms on ovarian cancer risk.
2. Methods
2.1. Study Population. Descriptions of the University of
Ume˚ a Northern Sweden Health and Disease Study (NSHDS)
and the New York University Women’s Health Study
(NYUWHS) have been provided previously [29–31]. Brieﬂy,
since 1985 the NSHDS has enrolled approximately 53756
women aged 30–65 through local health promotion inter-
vention programs in Northern Sweden. The NYUWHS
enrolled 14274 healthy women aged 34–65 years at a
breast cancer screening center in New York City between
1985 and 1991. Each study cohort collected information
about medical history, reproductive history, family history
of cancer, medications, smoking history, and diet during
enrollment and/or followup. Blood collected at enrollment
and any subsequent visits was processed according to
standardized procedures within each cohort. In the NSHDS
cohort,bloodwascollected,centrifuged,andplasmaaliquots
were frozen at −80
◦C and transferred within 1 week to
a −80
◦C central storage facility (the Northern Sweden
Medical Research Biobank). In the NYUWHS cohort, blood
was drawn, collection tubes were kept covered at room
temperature (21–25
◦C) for 15 minutes, then at 4◦Cf o r
60 minutes to allow clot retraction, and then centrifuged
for 25 minutes. After centrifugation, serum samples were
divided into aliquots and immediately stored at -80
◦Ca t
the local site. Participants who reported being pregnant or
using exogenous hormones within 6 months of enrollment
werenoteligiblefortheNYUWHScohortorforcase-control
selection from NSHDS.
2.2. Case Ascertainment. In the NSHDS, cohort linkages
to regional and national cancer registries and to all-cause
mortality registries were used to capture cases of incident
invasive epithelial ovarian cancer. In the NYUWHS cohort,
case ascertainment was achieved through self report on
followup questionnaires and through linkages with state
tumor registries in New York, New Jersey, and Florida.
Medical records were obtained to verify reported events. As
of November 1, 2005, a total of 192 invasive ovarian cancer
cases (107 from the NSHDS and 85 from the NYUWHS) had
been identiﬁed. Twenty-two nonepithelial ovarian cancer
cases (8 from the NSHDS and 14 from the NYUWHS) were
excluded from this study because they did not meet the
criteria of being invasive epithelial ovarian cancer. For the
currentstudy,therewereatotalof170invasiveEOCcases(71
from NYUWHS and 99 from NSHDS). However, two cases
fromtheNSHDScohorthadonlyDNAavailableforanalysis,
andwereonlyincludedinthemainVDRgenotypinganalysis
[26].
2.3. Selection of Controls. For each case, two controls were
randomly selected from cohort members who were alive
and free of cancer at the time of diagnosis of the case.
Controlswerealsomatchedtothecaseoncohort(NYUWHS
or NSHDS), age at entry (±6 months) and date of blood
donation (±15 days). Seventeen cases from the NYUWHS
cohort had only one eligible matched control because 10
controls had a complete bilateral oophorectomy before the
diagnosis date of the case and seven cases could not be
suﬃciently closely matched to a second control on date
of blood donation (strict matching is required to control
for seasonal eﬀects of vitamin D). Of the potential 323
eligible controls in total (198 from the NSHDS, 125 from the
NYUWHS), seven were excluded from the NSDHS because
either the control or matching case did not have plasma
available.
The institutional review boards of New York University
School of Medicine and the Regional Ethical Committee
of the University of Ume˚ a, Sweden, and the Swedish Data
Inspection Board reviewed and approved this study.
2.4. Laboratory Methods. Serum 25(OH)D was measured
at the University of Ume˚ a using a gamma-B 25-hydroxy
vitamin D radioimmunoassay (Immunodiagnostic Systems
(IDS), Inc.). Acetonitrile extraction of 25(OH)D was fol-
lowed by incubation with radioionidated tracers and sheep
antibodies to 25(OH)D. Antibody-bound tracer is inversely
proportional to the concentration of 25(OH)D. Samples
from each cohort and case-control set were assayed together
in the same laboratory batch. Quality controls and study
samples were distributed randomly throughout the batches
and the laboratory personnel were blinded to the samples’
case-control status. The intra- and interbatch coeﬃcients of
variation were 17.7% and 24.6% for NSHDS, respectively.
For NYUWHS, the intra- and interbatch coeﬃcients of
variation were 16.6% and 16.2%, respectively.
Genotyping was performed at New York University
School of Medicine. Methods, quality control procedures,
and genotyping success rates have been reported previously
[26].
2.5. Statistical Analysis. 25(OH)D values were log2 trans-
formed to reduce departures from the normal distribution
(the log2 transformation is useful for estimating odds ratios
associated with a doubling in vitamin D levels). Two control
participantsintheNYUWHScohortwithoutlyingvaluesfor
25(OH)D (>150nmol/L) were set to missing. Odds ratios
from analyses including or excluding these participants didJournal of Oncology 3
not diﬀer appreciably. Linear regression and ANOVA were
used to test whether 25(OH)D levels diﬀered according
to baseline characteristics. Conditional logistic regression,
which allows for the matched design, was used to evaluate
the association between serum concentration of 25(OH)D
and risk of EOC. Because cases were individually matched
to controls for laboratory batch and date of sampling (i.e.,
season), these variables were controlled for by design when
25(OH)D was modeled as a continuous variable. To create
meaningful tertiles of 25(OH)D for categorical analysis,
however, the 25(OH)D values needed to be laboratory batch
and season, to prevent individuals from being arbitrarily
included in a tertile simply on the basis of their season of
blood draw or inclusion in a particular batch. The adjust-
ment for laboratory batch was done by ﬁrst regressing the
log-transformed 25(OH)D values on season, age, and BMI
(the three variables that were associated with 25(OH)D) and
computing the residuals within each cohort. We then com-
puted the mean residual for each laboratory batch and sub-
tracted the appropriate batch mean from each individual’s
log-transformed vitamin D value to center each batch at the
grand mean for each cohort. We then adjusted for seasonal
eﬀects by performing a nonparametric local regression (Proc
Loess, SAS) of 25(OH)D values on day of the year of blood
donation and used the residuals to create cohort-speciﬁc
tertiles [32]. Potential confounders, speciﬁcally reproductive
history (parity, number of full-term pregnancies, and age
at ﬁrst full-term pregnancy), age at menarche, menopausal
status at enrollment, history of oral contraceptive use at
baseline, body mass index at enrollment, and smoking status
at baseline (never, current, former) were considered in
the logistic regression models. However, the only variables
signiﬁcantly diﬀerent between cases and controls were parity
a n do r a lc o n t r a c e p t i v eu s e( b o t hc a t e g o r i z e da se v e r / n e v e r ) .
Therefore, multivariate models included only these two vari-
ables (age and date of blood donation which were controlled
for by the matched design and use of the conditional logistic
regression model). An indicator variable for sample type
(serum versus plasma) also was examined as a potential
interaction term. We also conducted analyses excluding
individuals diagnosed within ﬁve years of blood donation,
and evaluated the vitamin D-ovarian cancer relationship
within histological subtypes, and by stage (I-II versus III-
IV), grade, BMI (dichotomous variable <25 versus ≥25),
oral contraceptive use (ever versus never), and VDR SNP
genotype (assuming a codominant model). Haplotypes were
estimated from genotype data using PHASE version 2.1.1
(http://www.stat.washington.edu/stephens/phase.html)a n d
odds ratios for the interaction between having zero, one,
or two copies of the haplotype and 25(OH)D levels were
determined using conditional logistic regression. We used
SAS software (version 9.1, SAS institute, Cary, NC) for all
statistical analyses.
3. Results
The characteristics of the study participants from each
cohort at baseline have been described previously [26]. An
abbreviated description is shown in Table 1. The median age
atenrollmentwas52and55yearsforNSHDSandNYUWHS
participants, respectively. NSHDS cases had a median of 4.6
years between blood donation and diagnosis and NYUWHS
cases were diagnosed an average of 7.0 years after blood
donation.NSHDScaseswerelesslikelythanNSHDScontrols
to have ever been pregnant (78% versus 89%, P = .01)
and to have ever taken oral contraceptives (33% versus 45%,
P = .03). NYUWHS cases and controls were not signiﬁcantly
diﬀerentwithregardtotheirbaselinecharacteristics.Regard-
ing diﬀerences between cohorts, NYUWHS controls were
more likely than NSHDS controls to be nulliparous (31%
versus 11%, P<. 0001), more likely to be premenopausal at
baseline (42% versus 28%, P = .0 1 ) ,l e s sl i k e l yt oh a v eu s e d
oral contraceptives (32% versus 45%, P = .03), more likely
to have smoked (61% versus 43%, P = .01), and had higher
25(OH)D levels (45.8 versus 39.4nmol/L, P = .04). Cases
andcontrolsdidnotdiﬀerwithregardtogenotype frequency
at any of the four VDR SNP sites for either of the cohorts
[26].
Table 2 shows 25(OH)D by characteristics of controls for
the NSHDS and NYUWHS cohorts. In both cohorts, median
25(OH)D levels were higher in women who were older at
enrollment and in women who had lower BMI, and were
somewhat higher in women who were ever parous and had
used oral contraceptives. However, the two cohorts diﬀered
with regard to smoking status: in the NYUWHS, current
smokers had higher median 25(OH)D levels (50nmol/L in
current versus ∼45nmol/L in former and never smokers),
while smoking in the NSHDS showed a somewhat opposite
relationship with 25(OH)D (∼38nmol/L in current and
former versus 40nmol/L in never smokers). 25(OH)D was
onlymodestlyrelatedtoVDRgenotypeintheNSHDScohort
at the Bsm1 (P = .16) and Taq1 (P = .19) loci (Table 3). In
both cohorts, women with two copies of the baT haplotype
(associated with the Bsm1 G, Apa1 G, and Taq1 Ta l l e l e
combination) had higher levels of circulating 25(OH)D,
although the tests for trend were not statistically signiﬁcant
(Table 3).
We did not observe an overall association between
vitamin D and ovarian cancer when 25(OH)D was modeled
on the continuous (multivariate adjusted OR for a doubling
in vitamin D levels = 1.1, 95% CI: 0.7–1.7 ) or categorical
scale (Table 4). There was some evidence of interaction
between 25(OH)D and cohort (P = .07), though cohort-
speciﬁc odds ratios do not support an association with
risk in either cohort (Table 4). The lack of association
between vitamin D and ovarian cancer remained after
controlling for parity and oral contraceptive use. We did
not observe any signiﬁcant diﬀerences in the relationship
between 25(OH)D and ovarian cancer by season of blood
collection, BMI (<25versus≥25kg/m2), menopausal status
at enrollment,VDR SNP genotype or haplotype, tumor stage
(I-II versus III-IV), grade, or histological subtype (serous
versus mucinous, clear cell, and endometriod) (data not
shown). Odds ratios for 25(OH)D and risk of ovarian cancer
did not change appreciably in analyses restricted to 74
matched sets in which cases were diagnosed ﬁve or more
years after blood donation (OR for the highest versus lowest
tertile = 0.9, 95% CI: 0.46–1.72).4 Journal of Oncology
Table 1: Characteristics of invasive epithelial ovarian cancer cases and matched controls, NYUWHS and NSHDS cohorts.
Characteristic
NYUWHS NSHDS
Cases(n = 71) Controls(n = 125) Cases(n = 97) Controls(n = 191)
Age at sampling, median (25%–75%), y 55(47–62) 55(46–62) 52(50–60) 51(50–60)
Time to diagnosis,
∗median (25%–75%), y 7.0(3.7–9.5) — 4.6(2.0–7.1) —
BMI at sampling, median (25%–75%),
kg/m2 25(22–28) 25(23–28) 25(23–28) 25(23–28)
Menopausal status at enrollment,†n (%)
Premenopausal 29(40.8) 52(41.6) 30(30.9) 53(27.7)
Postmenopausal 42(59.2) 73(58.4) 67(69.1) 138(72.3)
Parity, † ,‡ n (%)
Never 28(39.4) 39(31.2) 18(22.5) 19(11.0)
Ever 43(60.6) 86(68.8) 62(77.5) 153(89.0)
OC use, † ,‡ n (%)
Never 39(70.9) 63(68.5) 54(67.5) 89(54.6)
Ever 16(29.1) 29(31.5) 26(32.5) 74(45.4)
Unknown
Smoking status, † n (%)
Never 25(40.3) 38(38.8) 53(61.6) 100(56.8)
Ever 37(59.7) 60(61.2) 33(38.4) 76(43.2)
25(OH)D, median (25%–75%),nmol/L 47.8(31.4–64.5) 45.8(28.1–59.8) 37.6(29.5–46.5) 39.4(32.8–47.8)
∗Diﬀers signiﬁcantly between NYUWHS and NSHDS cases at P = .0001.
†NYUWHS and NSHDS controls diﬀer signiﬁcantly (P<. 05) with regard to age at menarche, menopausal status, parity, ever use of oral contraceptives,
smoking status, and 25(OH)D.
‡Case-control diﬀerences signiﬁcant only for NSHDS for parity (P = .01) and for oral contraceptives use (P = .03).
4. Discussion
In the current study, we did not observe an association
between circulating levels of 25(OH)D and risk of epithelial
o v a r i a nc a n c e r .T h el a c ko fa na s s o c i a t i o nr e m a i n e da f t e r
controlling for potential confounders, excluding cases diag-
nosed within 5 years of blood donation, and considering
subgroups deﬁned by genetic variation in the VDR,t u m o r
characteristics (i.e., stage, grade, and histological subtype),
menopausal status, and BMI.
Initial support for a protective role for vitamin D was
providedbyecologicalstudiesshowinganinverseassociation
between UV-B exposure and ovarian cancer incidence or
mortality rates [7–10]. However, research conducted with
this type of study design cannot elucidate the temporal
association between exposure and disease. Case-control and
cohortstudiesofdietaryvitaminDintakeandriskofovarian
cancer have been inconsistent [11–16]. The results of our
study are in agreement with the overall results of Tworoger et
al. [25], the only other prospective study of ovarian cancer to
report on circulating 25(OH)D to date. Our study similarly
found that the lack of association between serum 25(OH)D
and risk of ovarian cancer did not diﬀer by VDR genotype
[28]. However, Tworoger et al. found an inverse association
for 25(OH)D among women with BMI ≥ 25kg/m2 [25],
which was not observed in the current study.
Consistent with previous studies [33–37], higher BMI
was associated with lower circulating 25(OH)D in both
cohorts. Vitamin D is fat-soluble and studies in obese per-
sons and mice have shown increased storage and decreased
bioavailability of vitamin D in fat cells [38, 39]. We also
observed that parity was associated with higher 25(OH)D;
whichisinagreementwithasimilarobservationinthePLCO
Cancer Screening Trial [37]. Contrary to some previous
reports [37, 40, 41], we observed a positive relationship
between age and 25(OH)D, which showed increased levels
of vitamin D in the 50–60 year age group as compared
with younger women. This may be due to an increased
intake of calciumand vitamin D-rich foods and supplements
around the time of menopause in an eﬀort to prevent or
treatosteoporosis.Oralcontraceptiveusewasassociatedwith
highermedian25(OH)Dlevelsinourstudy;previousstudies
have found a similar relationship in current OC users [17,
42, 43]. We also found that the Bsm1 G, Apa1 G, and Taq1
Th a p l o t y p e , in the VDR gene was modestly associated with
higher 25(OH)D. Publications on the relationship between
VDR genotype and levels of 25(OH)D have been fairly
inconsistent. In the Physicians Health Study Cohort, the
Bsm1 genotype was not related to total 25(OH)D levels,
although the BB genotype was associated with higher index
of free 25(OH)D and with higher 1,25(OH)2Dl e v e l si n
older men [44]. The BB genotype was also associated with
higher 25(OH)D in a small Finnish study (n = 93) that
collected all blood samples in the winter when skin synthesis
of vitamin D is very low [45]. However, a large study of
2845 women found no association between any VDR SNPs
genotype and 25(OH)D [46]. Individuals with two copies
of the bAT haplotype (Bsm1 G, Apa1 T, and Taq1 T) hadJournal of Oncology 5
Table 2: Circulating 25(OH)D levels by baseline characteristics, NYUWHS and NSHDS controls.
Characteristic∗
25(OH)D by Cohort (nmol/L)
NYUWHS NSHDS
N Median (25%–75%) N Median (25%–75%)
Age at sampling, y
≤50 years 42 40.5 (24.6–64.0) 91 37.5 (24.1–53.8)
50–60 years 46 45.9 (30.7–66.7) 71 43.7 (28.4–68.1)
>60 years 35 44.9 (36.0–59.7) 29 39.4 (33.4–58.9)
P-trend (continuous) .15 .007
BMI at enrollment, kg/cm2
<25 60 51.6 (31.3–67.2) 89 43.4 (29.7–65.8)
25–29 39 43.4 (29.7–53.8) 69 35.8 (24.1–50.2)
≥30 21 32.0 (25.5–44.6) 26 38.3 (24.8–61.0)
P-trend (continuous) .004 .05
Menopausal status at enrollment
Premenopausal 51 37.5 (25.1–63.6) 53 34.8 (23.4–49.5)
Postmenopausal 72 45.6 (32.7–67.2) 138 42.2 (28.1–65.8)
P-value .03 .002
Parity
Never 39 41.9 (29.7–65.8) 19 35.8 (21.9–53.4)
Ever 84 45.6 (29.4–64.0) 153 39.7 (25.6–61.8)
P-value .49 .14
Oral contraceptives use
Never 62 44.6 (30.9–68.1) 89 38.6 (24.8–61.0)
Ever 28 49.5 (30.1–61.4) 74 42.5 (24.8–62.2)
P-value .46 .67
Smoking status
Never 37 45.9 (30.7–61.4) 100 40.8 (26.7–64.0)
Former 39 44.6 (31.6–66.7) 40 38.1 (25.5–60.1)
Current 20 49.9 (27.9–66.3) 36 37.5 (22.0–54.9)
P-value .62 .12
Season
Jan–Mar 29 38.1 (26.7–45.9) 63 34.1 (24.1–58.9)
Apr–Jun 26 42.5 (26.2–53.8) 44 40.8 (29.2–60.1)
Jul–Sep 40 49.9 (30.7–69.1) 16 46.2 (35.8–62.2)
Oct–Dec 28 55.7 (34.3–65.3) 68 43.4 (24.3–62.2)
P-value .13 .02
∗All variables had missing data for fewer than 7 controls except for NHSDS: parity (19 missing), oral contraceptives use (28 missing), and smoking (15
missing), and for NYUWHS: oral contraceptives use (33 missing) and smoking (27 missing).
lower levels of 25(OH)D than individuals with 0 or 1 copy
(P-trend = .09) [46]. Individuals without any copies of
baT (Bsm1 G, Apa1 G, and Taq1 T) in the current study
(which would include all individuals with two copies of the
bAT haplotype) had lower 25(OH)D levels, thus providing
indirect support for the previous ﬁnding.
This study limitations include the use of only one sample
to determine each participant’s 25(OH)D status. However,
in a preliminary reproducibility study of 25(OH)D among
16 NYUWHS participants with at least 3 annual visits,
the intraclass correlation coeﬃcient was quite high (0.71),
suggesting stability of this metabolite from visit to visit,
which has been observed by others [47, 48]. The relatively
high coeﬃcient of variation for the 25(OH)D assay adds
random error to the measurements and may have attenuated
the association. Potential residual confounding and relatively
small sample size are additional limitations. Although we
had suﬃcient sample size to detect small diﬀerences between
cases and controls (a priori, we had 80% power to detect
am e a nd i ﬀerence of 6nmol/L between cases and controls),
we had limited ability to explore interactions. Previous
studies have demonstrated that vitamin D deﬁciency is more
common in Europe than the United States, and that in the
United States, the latitude of residence is inversely associated6 Journal of Oncology
Table 3: Circulating 25(OH)D levels by vitamin D receptor Fok1 genotype and Bsm1, Apa1, and Taq1 haplotype, NYUWHS and NSHDS
controls.
Characteristic
25(OH)D by Cohort (nmol/L)
NYUWHS NSHDS
N Median (25%–75%) N Median (25%–75%)
Fok1
C/C 50 42.2 (25.5–68.6) 68 37.0 (24.3–53.8)
C/T 56 46.9 (30.5–64.0) 92 42.5 (24.8–65.8)
T/T 17 48.8 (31.1–64.4) 29 36.0 (26.2–62.2)
P-trend .27 .28
Haplotype 1
(Bsm1G ,Apa1G ,a n dTaq1T )
0 copies 38 44.6 (32.0–53.8) 48 38.9 (24.1–60.5)
1 copies 60 44.6 (26.4–69.1) 93 38.6 (24.8–62.2)
2 copies 25 48.8 (30.7–63.1) 50 43.1 (26.4–62.2)
P-trend .71 .25
Table 4: Odds ratios for invasive epithelial ovarian cancer by tertile of 25(OH)D.
ORs for season-adjusted 25(OH)D tertiles P-trend
Tertile 1 Tertile 2 Tertile 3
NYUWHS ≤36.7nmol/L 36.8–57.7nmol/L ≥ 57.8nmol/L
n, case/control 22/42 23/43 26/38
Model 1
∗ 1.0(reference) 0.97(0.45–2.06) 1.35(0.59–3.09) 0.50
Model 2
† 1.0(reference) 1.13(0.39–3.27) 1.50(0.53–4.23) 0.44
NSHDS ≤34.0nmol/L 34.1–44.7nmol/L ≥ 44.8nmol/L
n, case/control 37/58 28/70 32/63
Model 1
∗ 1.0(reference) 0.62(0.33–1.11) 0.79(0.42–1.46) 0.49
Model 2
† 1.0(reference) 0.54(0.25–1.17) 0.83(0.38–1.81) 0.78
Combined cohorts Cohort-speciﬁc cut points Cohort-speciﬁc cut points Cohort-speciﬁc cut points
n, case/control 59/100 51/113 58/101
Model 1
∗ 1.0(reference) 0.74(0.46–1.20) 0.96(0.59–1.58) 0.88
Model 2
† 1.0(reference) 0.78(0.42–1.43) 1.09(0.59–2.01) 0.71
∗Conditional logistic regression model controlling for matching factors only: cohort, age at entry, and date of blood donation.
†Conditional logistic regression model controlling for matching factors and additionally adjusted for oral contraceptive use (ever/never) and parity
(ever/never) after exclusion of the participants with missing data for these variables (NYUWHS: n = 49, NSHDS: n = 49).
with vitamin D (reviewed in [49]). We anticipated that the
ranges of 25(OH)D values in the New York and Northern
Sweden populations would be lower than those reported
from lower latitudes [50, 51]. In the highest tertile, the
median value for 25(OH)D was 68.9nmol/L for NYUWHS
and 51.6nmol/L for NSHDS; somewhat lower than the
75nmol/L, that is, considered to be optimal for multiple
health outcomes [52] .F e ww o m e ni no u rs t u d yh a dl e v e l s
above 75nmol/L, thus we cannot rule out the possibility that
women with very high 25(OH)D levels may have a reduced
risk of ovarian cancer. Strengths of the study include the use
of samples collected before diagnosis, limiting the potential
for existing disease to inﬂuence vitamin D levels, the use of
circulating 25(OH)D as a composite measure of vitamin D
overall status, careful consideration of seasonal eﬀects, and
the use of a nested case-control design, which helps ensure
that the controls are comparable to the cases.
In conclusion, our ﬁndings do not provide support for
thehypothesisthatcirculatingvitaminDlevelsareassociated
with risk of invasive epithelial ovarian cancer later in life.
Larger studies are needed to evaluate gene-environment
interactionsandpotentialsubgroupswhichmaybeneﬁtfrom
vitamin D chemoprevention.
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